Abstract
81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.
| Original language | English |
|---|---|
| Pages (from-to) | 59-63 |
| Number of pages | 5 |
| Journal | New Trends in Experimental and Clinical Psychiatry |
| Volume | 14 |
| Issue number | 1 |
| Publication status | Published - 1998 |
Fingerprint
Keywords
- Depressive
- Haloperidol dosages
- Negative-positive symptoms
- Schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Depressive, negative and positive symptoms in schizophrenia : Response to different dosages of haloperidol. / Mauri, M. C.; Laini, V.; Steinhilber, C. P C; Boscati, L.
In: New Trends in Experimental and Clinical Psychiatry, Vol. 14, No. 1, 1998, p. 59-63.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Depressive, negative and positive symptoms in schizophrenia
T2 - Response to different dosages of haloperidol
AU - Mauri, M. C.
AU - Laini, V.
AU - Steinhilber, C. P C
AU - Boscati, L.
PY - 1998
Y1 - 1998
N2 - 81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.
AB - 81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.
KW - Depressive
KW - Haloperidol dosages
KW - Negative-positive symptoms
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=0031842724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031842724&partnerID=8YFLogxK
M3 - Article
VL - 14
SP - 59
EP - 63
JO - New Trends in Experimental and Clinical Psychiatry
JF - New Trends in Experimental and Clinical Psychiatry
SN - 0393-5310
IS - 1
ER -